Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Basilea names new commercial head

This article was originally published in Scrip

Executive Summary

Basilea Pharmaceutica, which develops products in the therapeutic areas of bacterial infections, fungal infections and oncology, has named David Veitch chief commercial officer – effective 1 September 2014. Mr Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access, and will report to chief executive officer Ronald Scott. Prior to joining the Basel, Switzerland-based firm, Mr Veitch was president of European operations at Savient Pharmaceuticals.

You may also be interested in...



Numbers Crunched: Reviewing Biopharma's FY 2019 Performance

The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel